| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 576.06B | 598.79B | 530.21B | 475.09B | 592.01B | 579.07B |
| Gross Profit | 576.06B | 653.20B | 577.73B | 469.88B | 539.73B | 514.55B |
| EBITDA | 0.00 | 77.48B | 42.07B | 52.85B | 45.90B | 41.75B |
| Net Income | 46.71B | 42.15B | 22.32B | 25.37B | 21.48B | 20.04B |
Balance Sheet | ||||||
| Total Assets | 1.88T | 1.77T | 1.56T | 1.51T | 1.38T | 1.26T |
| Cash, Cash Equivalents and Short-Term Investments | 737.01B | 664.26B | 21.87B | 21.36B | 21.79B | 23.13B |
| Total Debt | 41.51B | 52.60B | 40.26B | 46.20B | 47.43B | 60.34B |
| Total Liabilities | 1.49T | 1.40T | 1.23T | 1.21T | 1.08T | 982.51B |
| Stockholders Equity | 285.11B | 268.73B | 242.35B | 221.77B | 219.26B | 202.48B |
Cash Flow | ||||||
| Free Cash Flow | 88.51B | 83.59B | 66.98B | 65.08B | 110.35B | 59.83B |
| Operating Cash Flow | 92.79B | 87.99B | 70.55B | 71.65B | 72.73B | 31.87B |
| Investing Cash Flow | -98.88B | -77.60B | -70.93B | -73.28B | -81.56B | -51.37B |
| Financing Cash Flow | 12.05B | 4.86B | -11.48B | 8.56B | -35.86B | 21.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | HK$220.28B | 5.25 | 34.37% | 5.36% | 49.90% | 203.77% | |
78 Outperform | HK$418.91B | 6.24 | 17.99% | 3.15% | 9.40% | 79.93% | |
76 Outperform | HK$370.56B | 9.01 | 14.60% | 3.80% | 6.42% | 66.35% | |
76 Outperform | HK$409.24B | 6.04 | 18.41% | 3.31% | 15.08% | 23.13% | |
71 Outperform | HK$68.50B | 8.38 | 10.74% | 1.84% | 23.64% | 36.32% | |
71 Outperform | HK$156.30B | 11.29 | 9.41% | 3.86% | 51.04% | 24.56% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
The People’s Insurance Company (Group) of China Limited announced that its Vice President, Mr. Yu Ze, is under investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission for suspected serious violations of discipline and law. Despite the investigation, the company has stated that its management and operations remain unaffected.
The People’s Insurance Company (Group) of China Limited held its 2025 Investor Open Day, emphasizing the theme of ‘Practices and Outlook for the High-Quality Development of Non-Auto Insurance.’ This event underscores the company’s strategic focus on enhancing its non-auto insurance offerings, which may impact its market positioning and stakeholder interests.
The People’s Insurance Company (Group) of China Limited announced the successful passing of resolutions at its 2025 second extraordinary general meeting, including the approval of the 2025 interim profit distribution. The interim dividend, amounting to RMB3.317 billion, will be distributed to shareholders in December 2025, reflecting the company’s strong financial performance and commitment to shareholder returns.
The People’s Insurance Company (Group) of China Limited announced an update to its interim cash dividend for the six months ended June 30, 2025. The dividend is set at RMB 0.075 per share, with a corresponding payment in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09603214. The ex-dividend date is November 4, 2025, and the payment will be made on December 12, 2025. This announcement reflects the company’s commitment to returning value to its shareholders and may impact its financial positioning and investor relations positively.
The People’s Insurance Company (Group) of China Limited reported significant financial growth in its third quarterly report of 2025, with a notable increase in both total operating income and net profit attributable to owners. The company’s total assets and equity have also seen substantial growth, indicating a strong financial position and positive market performance.
The People’s Insurance Company (Group) of China Limited announced its plan to hold the 2025 Third Quarter Results Announcement through a text interaction session on October 31, 2025. This event will allow investors to engage with the company by submitting questions in advance, which will be addressed during the session, potentially impacting investor relations and market perceptions.
The People’s Insurance Company (Group) of China Limited has announced a board meeting scheduled for October 30, 2025, to review and approve the unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
The People’s Insurance Company (Group) of China Limited has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on October 30, 2025. The meeting will address resolutions concerning the 2025 interim profit distribution and amendments to the authorization plan for the Board of Directors. This announcement is significant as it outlines key corporate governance actions that could impact shareholder value and company operations.
The People’s Insurance Company (Group) of China Limited announced an update to its interim dividend for the six months ended 30 June 2025, declaring a dividend of RMB 0.075 per share. The update includes details on the date of shareholders’ approval, Hong Kong share register information, and withholding tax arrangements. This announcement is significant for stakeholders as it provides clarity on the financial returns and tax implications for both resident and non-resident shareholders, potentially impacting investor decisions and market perception.
The People’s Insurance Co (Group) of China has announced the composition of its board of directors and the establishment of five special committees under the board. This organizational structure aims to enhance the company’s strategic direction, risk management, and governance, potentially strengthening its position in the insurance industry and improving stakeholder confidence.
The People’s Insurance Company (Group) of China Limited has announced the appointment of Mr. Xu Xiang as a non-executive director, effective from September 29, 2025, following approval from the National Financial Regulatory Administration. This strategic appointment, which also includes Mr. Xu’s roles in the Risk Management & Consumers’ Rights and Interests Protection Committee and the Nomination and Remuneration Committee, is expected to enhance the company’s governance and oversight capabilities, potentially strengthening its market position and stakeholder confidence.